

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
APPLICATION

Inventor(s): BOUCHARD et al.

Appl. No.: 08 786,937

Series Code ↑

Serial No. ↑

Group Art Unit

1654

Examiner:

Delacroix-Muirhead

Atty. Dkt.

PMS

235299

960018PH/De

M#

Client Ref

Filed: January 22, 1997

Title: LHRH-ANTAGONISTS IN THE TREATMENT OF

(Our Deposit Account No. 03-3975)

(Our Order No.

11468

235299

C#

M#

Date:

June 3, 1999

Asst. Commissioner of Patents

Washington, D.C. 20231

Sir:



REPLY/AMENDMENT/LETTER

JUN 4 1999

MATRIX CUSTOMER
SERVICE CENTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in-absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed

- ☐ previously
☐ herewith

(No.)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims	17	**minus 20	0	x \$18/\$9 =	+ 0	103/203
3. Independent Claims	2	***minus 3	0	x \$78/\$39 =	+ 0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application).....add				+ \$260/\$130 =	+ 0	104/204
5. Original due Date: JUNE 3, 1999	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) (2 mos) (3 mos)	\$110/\$55 = \$380/\$190 = \$870/\$435 =	+ 0		115/215 116/216 117/217
7. Enter any previous extension fee paid since above original due date and subtract			-			
8.	Extension Fee Attached				+ 0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$/\$ =		+ 0	148/248
10. If IDS attached requires Official Fee,add			+ \$ =		+ 0	126
or if Rule 97(d) Petitionadd			+ \$ =			122
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$760/380 =		+ 0	146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$760/380 ea =		+ 0	149/249
13. Petition fee for					+ 0	
14.	TOTAL FEE ENCLOSED =				\$0	

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an Issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

By Atty: Ann S. Hobbs, Ph.D.

Reg. No. 36830

1100 New York Avenue, N.W.

Ninth Floor East Tower

Washington, D.C. 20005-3918

Tel: (202) 861-3000

Atty/Sec: ASH/maf

Sig:

Fax:

(202) 822-0944

Tel:

(202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

BOUCHARD, et al.

Appln. No.: 08/786,937

Filed: January 22, 1997



Group Art Unit: 1801

Examiner: Delacroix-Muirhead

13/C
H.G.J
6/8/99

FOR: LHRH-ANTAGONISTS IN THE
TREATMENT OF FERTILITY DISORDERS

* * * * *

June 3, 1999

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Official Action issued March 3, 1999, please enter the
following amendments and consider the following remarks.

IN THE CLAIMS:

Amend the claims as follows:

18. (Twice amended) The method according to claim 15 wherein after [the]
suppression of endogenous
inhibition of the action of natural LH caused by the LH-RH Antagonist, [the] follicle
growth
development is not externally stimulated but maintained by [endogenous]
endogenous gonadotropins.

20. (Twice amended) The method according to claim 16 wherein Cetrorelix
is administered subcutaneously in an amount of about 0.25 mg [or higher] to 1 mg
per day during a multiple dosing posology.

SUB
C 10/27

e2